BRIEF-Checkmate Pharmaceuticals Announces Start Of Phase 1B Trial Of CMP-001 In Combination With Anti-Pd-L1 Immunotherapy In Anti-Pd-1/Pd-L1 Resistant Advanced Non-Small Cell Lung Cancer
April 24 (Reuters) - CHECKMATE PHARMACEUTICALS:
* CHECKMATE PHARMACEUTICALS ANNOUNCES START OF PHASE 1B TRIAL OF CMP-001 IN COMBINATION WITH ANTI-PD-L1 IMMUNOTHERAPY IN ANTI-PD-1/PD-L1 RESISTANT ADVANCED NON-SMALL CELL LUNG CANCER Source text for Eikon: (Reuters.Briefs@thomsonreuters.com)